Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.

Trial Details

NCT ID
NCT04824950
Phase
NA
Sponsor
Centre Henri Becquerel
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Circulating tumor DNA monitoring
Locations (sample)
  • Lyon, France|45.74906,4.84789
  • Rouen, France|49.44313,1.09932

Key Eligibility Criteria

  • Patient over 18 years of age,
  • Suffering from a diffuse primary B lymphoma of the mediastinum, newly diagnosed locally on a biopsy with anatomopathological analysis according to …
  • All stages (I-IV)
  • All IPI scores (0-5)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →